Multivariable models of outcomes with [¹⁷⁷Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial.

ABSTRACT:

Background

[¹⁷⁷Lu]Lu-PSMA-617 (¹⁷⁷Lu-PSMA-617) prolonged life in patients with metastatic castration-resistant prostate cancer (mCRPC) in VISION (NCT03511664). However, distinguishing between patients likely and unlikely to respond remains a clinical challenge. We present the first multivariable models of outcomes with ¹⁷⁷Lu-PSMA-617 built using data from VISION, a large prospective phase 3 clinical trial powered for overall survival.

Methods

Adults with progressive post androgen receptor pathway inhibitor and taxane prostate-specific membrane antigen (PSMA)-positive mCRPC received ¹⁷⁷Lu-PSMA-617 plus protocol-permitted standard of care (SoC) or SoC alone. In this post hoc analysis, multivariable Cox proportional hazards mod

SUBMITTER: Herrmann K 

PROVIDER: S-EPMC11490806 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature